CTOs on the Move

Q S Pharma

www.qspharma.com

 
Q S Pharma LLC is a Marcus Hook, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.qspharma.com
  • 3 Chelsea Pkwy Ste 305
    Marcus Hook, PA USA 19061
  • Phone: 610.485.4270

Executives

Name Title Contact Details

Similar Companies

UAB Health System

The (University of Alabama at Birmingham) UAB Health System is an academic health center located in Birmingham, Alabama. UAB Hospital is the centerpiece of the UAB Health System. It was established in 1945 as the teaching hospital for the University of Alabama School of Medicine and, today, is one of the four largest academic medical centers in the United States.

EMINENT Services Corporation

EMINENT Services Corporation is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cynvenio Biosystems Inc

Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of cancer biomarkers in blood.

The Storch-Murphy Group

The Storch-Murphy Group is a Englewood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mela Sciences

At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.